GSK
HealthcareGSK plc
$49.02
$-0.61 (-1.23%)
Jan 5, 2026
Price History (1Y)
Analysis
GSK plc is a leading healthcare company with a presence in the global Drug Manufacturers - General industry. The company operates within the broader Healthcare sector and has a significant scale, reflected by its market capitalization of $99.21 billion, revenue of $32.17 billion (on a trailing 12-month basis), and approximately 68,629 employees. Financially, GSK demonstrates robust profitability with gross margins standing at 72.4%, operating margins at 32.6%, and profit margins at 17.1%. Returns on equity and assets are substantial, measuring 41.5% and 7.1%, respectively. The company's balance sheet shows a debt-to-equity ratio of 112.68, indicating significant leverage, while the current ratio of 0.84 suggests manageable short-term liquidity. Cash reserves stand at $3.31 billion, whereas total debt amounts to $17.75 billion. GSK's valuation metrics are as follows: its price-to-earnings (P/E) ratio on a trailing basis is 13.69, and forward P/E stands at 10.52. The company has a price-to-book of 9.10 and a price-to-sales ratio of 3.08. Revenue growth over the past year was 6.7%. Dividend yield is notably high at 340.0%, accompanied by a payout ratio of 47.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Visit website →Key Statistics
- Market Cap
- $99.21B
- P/E Ratio
- 13.69
- 52-Week High
- $49.63
- 52-Week Low
- $31.72
- Avg Volume
- 4.35M
- Beta
- 0.25
- Dividend Yield
- 340.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NYQ
- Country
- United Kingdom
- Employees
- 68,629